Clinicopathological Characteristics of Hepatocellular Carcinoma at a Tertiary Hospital: A Retrospective Study
), Noza Hilbertina(2), Aswiyanti Asri(3), Yenita -(4), Loli Devianti(5),
(1) Department of Anatomical Pathology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
(2) Department of Anatomical Pathology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia; Anatomical Pathology Laboratory, Dr. M. Djamil General Hospital, Padang, Indonesia
(3) Department of Anatomical Pathology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia; Anatomical Pathology Laboratory, Dr. M. Djamil General Hospital, Padang, Indonesia
(4) Department of Anatomical Pathology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia; Anatomical Pathology Laboratory, Dr. M. Djamil General Hospital, Padang, Indonesia
(5) Department of Anatomical Pathology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
Corresponding Author
Abstract
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer globally and shows significant regional variations in clinicopathological characteristics. Limited data exist on HCC patterns in Indonesia, particularly in West Sumatra. This study aimed to characterize the clinicopathological features of HCC at Dr. M. Djamil Hospital, Padang, from 2021to2024.
Methods: A descriptive retrospective study was conducted using medical records and histopathological re-evaluation of 46 HCC cases. Specimens were examined for demographic data, tumor characteristics, histopathological subtypes according to the WHO 2019 classification, differentiation grade, lymphovascular invasion, and background liver pathology.
Results: The median age was 56 years, with male predominance (60.9%). Most specimens were resection specimens (60.9%) with tumor size ≥4 cm in 47.8% of cases and single nodules in 52.1%. Clear cell (39.1%) and macrotrabecular massive (37.0%) were the predominant subtypes, contrasting with global data showing NOS predominance. Most tumors were moderately differentiated (63.0%), with lymphovascular invasion present in 65.2% and cirrhotic background in 58.7% of cases
Conclusion: HCC in West Sumatra demonstrates distinct histopathological patterns, with a predominance of clear cell and macrotrabecular massive subtypes and high rates of lymphovascular invasion. These finding suggest histopathological features associated with aggressive tumor behavior (particularly macrotrabecular massive subtype and lymphovascular invasion), although no clinical outcome or survival analysis was performed.
Keywords
References
McGlynn KA, London WT. The Global Epidemiology of Hepatocellular Carcinoma: Present and Future. Clin Liver Dis. 2011;15(2):223–43.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–89.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Liu Y, Liu L. Changes in the epidemiology of hepatocellular carcinoma in Asia. Cancers (Basel). 2022;14(18):4554.
Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: A case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol. 2007;22(7):1104–11.
Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: Implications on prognosis and management. ESMO Open. 2016;1(2):1–16.
Alsudaney M, Ayoub W, Kosari K, Koltsova E, Mohammed N, Adetyan H, et al. Pathophysiology of liver cirrhosis and risk correlation between immune status and the pathogenesis of hepatocellular carcinoma. Hepatoma Res. 2025;11:7.
Torbenson MS. Hepatocellular carcinoma. In: WHO Classification of Tumours Editorial Board, editor. Digestive System Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
Loy LM, Low HM, Choi JY, Rhee H, Wong CF, Tan CH. Variant Hepatocellular Carcinoma Subtypes According to the 2019 WHO Classification: An Imaging-Focused Review. Am J Roentgenol. 2022;219(2):212–23.
Sweed D, Sweed E, Moaz I, Mosbeh A, Fayed Y, Elhamed SMA, et al. The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt. World J Surg Oncol. 2022;20(1):1–20.
Lee Y, Park H, Lee H, Cho JY, Yoon YS, Choi YR, et al. The clinicopathological and prognostic significance of the gross classification of hepatocellular carcinoma. J Pathol Transl Med. 2018;52(2):85–92.
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.
Radu IP, Scheiner B, Schropp J, Delgado MG, Schwacha-Eipper B, Jin C, et al. The influence of sex and age on survival in patients with hepatocellular carcinoma. Cancers (Basel). 2024;16(23):4012.
Hasan I. Profil klinis dan kesintasan pasien karsinoma sel hati di rumah sakit rujukan tersier Indonesia tahun 2015–2021. J Penyakit Dalam Indones. 2023;10(2):59–66.
Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin North Am. 2017;46(2):365–91.
Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, et al. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology. 2018;68(1):103–12.
Yamashita Y, Tsuijita E, Takeishi K, Fujiwara M, Kira S, Mori M, et al. Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Ann Surg Oncol. 2012;19:2027–34.
Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–39.
Bartolini I, Nelli T, Russolillo N, Cucchetti A, Pesi B, Moraldi L, et al. Multiple hepatocellular carcinoma: Long-term outcomes following resection beyond actual guidelines. An Italian multicentric retrospective study. Am J Surg. 2021;222(3):599–605.
Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):1312–27.
Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol. 2021;11:719525.
Article Metrics
Abstract View
: 93 times
Download : 50 times
DOI: 10.24871/271202637-44
Refbacks
- There are currently no refbacks.
